Prescription Opioid Misuse in US Older Adults: Associated Comorbidities and Reduced Quality of Life in the National Epidemiologic Survey of Alcohol and Related Conditions-III

Instructions

Click the red REGISTER button to pay the $10 fee and take the posttest
Click here to return to the JCP CME article.

Overview

How does prescription opioid misuse affect people who are 50 years old and older? What factors should clinicians look for when screening? Review this CME.


Read the whole article at psychiatrist.com here:
Prescription Opioid Misuse in US Older Adults: Associated Comorbidities and Reduced Quality of Life in the National Epidemiologic Survey of Alcohol and Related Conditions-III

© Copyright 2019 Physicians Postgraduate Press, Inc.

Target Audience

Psychiatrists

Learning Objectives

Recognize factors associated with prescription opioid misuse in older adults, including psychiatric, physical health, and substance use correlates

Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Activity opens: 
11/19/2019
Activity expires: 
12/31/2021
Cost:
$10.00
Rating: 
0

CME Background

Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.

CME Objective

After studying this article, you should be able to:

  • Recognize factors associated with prescription opioid misuse in older adults, including psychiatric, physical health, and substance use correlates

Statement of Need and Purpose

The US opioid epidemic is a public health emergency. Adults aged 50 years and older have high rates of prescription opioid use, and misuse is associated with concurrent medical conditions and reduced quality of life. Clinicians need education on identifying older adults with prescription opioid misuse to be able to coordinate care to reduce the prevalence of opioid use disorder and its correlates.

Release, Expiration, and Review Dates

This educational activity was published in November 2019 and is eligible for AMA PRA Category 1 Credit™ through December 31, 2021. The latest review of this material was October 2019.

Disclosure of Off-Label Usage

The authors have determined that, to the best of their knowledge, no investigational information about pharmaceutical agents or device therapies that is outside US Food and Drug Administration–approved labeling has been presented in this article.

Funding/Support

The NESARC-III is funded by the National Institute on Alcohol Abuse and Alcoholism, and this work was supported by the National Institutes of Health (NIH) via R01AA025684, R01CA212517, R01DA031160, R01DA036541, R01DA042146, and R01DA043696.

Role of the sponsor

NIH had no role in this study’s design, the collection, analysis or interpretation of data, the writing of the report, or the decision to submit the paper for publication.

Additional information

The original dataset for the National Epidemiologic Survey of Alcohol and Related Conditions-III (NESARC-III) is available from the National Institute on Alcohol Abuse and Alcoholism (NIAAA; https://www.niaaa.nih.gov/research/nesarc-iii).

Faculty Affiliation

Ty S. Schepis, PhD*
Department of Psychology, Texas State University, San Marcos, Texas
 

Sean Esteban McCabe, PhD
Center for the Study of Drugs, Alcohol, Smoking and Health, School of Nursing, University of Michigan; Institute for Research on Women and Gender, University of Michigan; and Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan

*Corresponding author: Ty S. Schepis, PhD, Department of Psychology, Texas State University, 601 University Dr, San Marcos, TX 78666 (schepis@txstate.edu).

Financial Disclosure

All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past year, Marlene P. Freeman, MD, Editor in Chief of The Journal of Clinical Psychiatry, has received research funding from JayMac and Sage; has been a member of the advisory boards for Otsuka, Alkermes, and Sunovion; has been a member of the Independent Data Safety and Monitoring Committee for Janssen; and, as a Massachusetts General Hospital (MGH) employee, works with the MGH National Pregnancy Registry, which is sponsored by Teva, Alkermes, Otsuka, Actavis, and Sunovion, and works with the MGH Clinical Trials Network and Institute, which receives research funding from multiple pharmaceutical companies and the National Institute of Mental Health. No member of the CME Institute staff reported any relevant personal financial relationships.

Drs Schepis and McCabe have no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Price

Cost:
$10.00
Please login or register to take this activity.

Register for free on our site to participate in this and many other free CME courses. There is a $10 processing fee for this activity.